Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose imatinib with response-adapted escalation in newly diagnosed chronic-phase CML
ACTRN12607000614493Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Overall rates and duration of complete cytogenetic response and molecular response. Started Oct 2002; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12607000614493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000614493.